Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Computational toxicology in drug development.
Muster W, Breidenbach A, Fischer H, Kirchner S, Müller L, Pähler A. Muster W, et al. Among authors: muller l. Drug Discov Today. 2008 Apr;13(7-8):303-10. doi: 10.1016/j.drudis.2007.12.007. Epub 2008 Feb 20. Drug Discov Today. 2008. PMID: 18405842 Review.
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.
Sutter A, Amberg A, Boyer S, Brigo A, Contrera JF, Custer LL, Dobo KL, Gervais V, Glowienke S, van Gompel J, Greene N, Muster W, Nicolette J, Reddy MV, Thybaud V, Vock E, White AT, Müller L. Sutter A, et al. Among authors: muller l. Regul Toxicol Pharmacol. 2013 Oct;67(1):39-52. doi: 10.1016/j.yrtph.2013.05.001. Epub 2013 May 10. Regul Toxicol Pharmacol. 2013. PMID: 23669331
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Müller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P. Kirkland D, et al. Among authors: muller l. Mutat Res. 2007 Mar 30;628(1):31-55. doi: 10.1016/j.mrgentox.2006.11.008. Epub 2007 Jan 13. Mutat Res. 2007. PMID: 17293159
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, DeGeorge J, De Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L. Müller L, et al. Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211. doi: 10.1016/j.yrtph.2005.12.001. Epub 2006 Jan 18. Regul Toxicol Pharmacol. 2006. PMID: 16412543
Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L, Gocke E, Lavé T, Pfister T. Müller L, et al. Toxicol Lett. 2009 Nov 12;190(3):317-29. doi: 10.1016/j.toxlet.2009.04.003. Epub 2009 Apr 10. Toxicol Lett. 2009. PMID: 19443141
Toxicol. Lett.; Gocke, E., Muller, L., Pfister, T., 2009b. EMS in Viracept-initial ('traditional') assessment of risk to patients based on linear dose response relations. Toxicol. Lett.; Gocke, E., Muller, L., Ballantyne, M., Whitwell, J., Muller …
Toxicol. Lett.; Gocke, E., Muller, L., Pfister, T., 2009b. EMS in Viracept-initial ('traditional') assessment of risk to patie …
2,467 results